Invitae borrows against the future
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
Ortho Clinical takes a haircut
Discount pricing and poor first day defies the recent trend for floating device makers.
Medtech deal-making stands firm in difficult times
It takes more than a pandemic to stop medical device companies merging.
Smaller device makers put in a muted performance
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
Invitae ends medtech merger drought with ArcherDX deal
The cash-and-stock deal, worth $886m up front, is the first major liquid biopsy acquisition since Roche bought Foundation Medicine.
